Repligen posts record Q3 revenue, raises 2026 guidance after closing BioLife deal

Repligen Corporation reported financial results for the third quarter of 2026, the period ended September 30, 2026, on October 27, 2026. Third quarter revenue was $209 million, a year-over-year increase of 11% as reported and 12.5% organic.¹

The company closed its acquisition of BioLife Solutions. The acquisition strengthens Repligen's position in cell therapy by adding a differentiated, deeply embedded consumables platform with recurring revenue, commercial-stage exposure, and strong customer workflow integration, and is expected to enhance the company's long-term growth, margin profile, and earnings power.¹ The financial guidance for full year 2026 includes the expected impact of BioLife Solutions from the closing date of October 6, 2026.¹

On the facilities side, Repligen opened a new training facility abroad. The company opened a new Repligen Training & Innovation Center in Seoul, South Korea, on October 23, 2026, underscoring its commitment to a market the company called one of the world's leading hubs for biologics and CDMO manufacturing.¹

On guidance, the company raised its outlook. For full year 2026, the company now guides to total reported revenue of $844 million to $852 million, representing reported growth of 14.5% to 15.5% and organic growth of 12% to 13%, with adjusted diluted earnings per share of $2.05 to $2.09.¹ The revenue guidance reflects a neutral impact from foreign currency and an approximately 2.5 point tailwind from inorganic growth primarily from the BioLife acquisition net of the divestiture of Polymem.¹

On the balance sheet, cash, cash equivalents and marketable securities at September 30, 2026, were $863 million, compared to $768 million at December 31, 2025.¹ The quarter's GAAP results reflected a one-time charge: Q3 loss from operations was $29.5 million, primarily driven by an intangible asset impairment charge, compared to income from operations of $16.8 million a year earlier.¹